Marketed Products
RAPTIVA®
Full Prescribing Information / RAPTIVA® Product Site
RAPTIVA® (efalizumab) was developed through a collaboration between Genentech and XOMA, and received FDA approval in October of 2003 as the first FDA-approved biologic therapy to provide continuous control of chronic moderate-to-severe plaque psoriasis in adults age 18 or older who are candidates for systemic therapy or phototherapy. RAPTIVA® is now approved in more than 44 countries for moderate-to-severe plaque psoriasis.
RAPTIVA® is a humanized therapeutic antibody designed to selectively block the activation, reactivation and trafficking of T-cells that lead to the development of psoriasis. In psoriasis, immune cells called T-cells become overactive, triggering a chain of events that speeds up the life and subsequent death cycles of skin cells. Dead skin cells pile up on the surface, forming red, scaly patches known as plaques. With psoriasis, an individual can suffer various degrees of unwanted redness, flaking, itching, and sometimes pain and bleeding. RAPTIVA® prevents T-cells from becoming activated and entering the skin, which in turn, inhibits plaque formation allowing for psoriasis symptoms to clear.
XOMA earns a mid single-digit royalty on worldwide sales of RAPTIVA®. Worldwide RAPTIVA ® sales totaled $213 million in 2007.
LUCENTIS®
Full Prescribing Information (PDF) / LUCENTIS® Product Site
LUCENTIS® (ranibizumab injection) is the first marketed therapeutic product manufactured under XOMA’s license using XOMA’s bacterial cell expression technology. LUCENTIS® received U.S. FDA approval for the treatment of neovascular wet age-related macular degeneration (wet AMD), a leading cause of blindness in people over the age of 55 in the U.S.
LUCENTIS ® is an antibody fragment designed to bind and inhibit VEGF-A, a protein that is believed to play a critical role in the formation of new blood vessels. In wet AMD, these blood vessels grow under the retina and leak blood and fluid causing rapid damage to the macula, the portion of the eye responsible for fine, detailed central vision.
AMD is a major cause of gradual or sudden, painless, central visual loss in the elderly, brought on by deterioration of the macula. There are two forms of AMD wet and dry. Approximately 1.7 million Americans have the advanced form of this condition.
U.S. sales of LUCENTIS® totaled $815 million in 2007. XOMA earns royalties on U.S. sales of bacterial cell expression-enabled products, including LUCENTIS® and CIMZIA®, of 0.5 percent to 3.0 percent of sales.
CIMZIA®
Full Prescribing Information / CIMZIA® Product Site
CIMZIA® (certolizumab pegol, CDP870) is the second marketed product manufactured under XOMA’s license using XOMA’s bacterial cell expression technology. CIMZIA® received U.S. FDA approval in April 2008 for the treatment of Crohn’s disease and the U.S. FDA accepted the regulatory application of CIMZIA® for rheumatoid arthritis (RA) in February of 2008. CIMZIA ® is also in clinical trials for the treatment of psoriasis.
CIMZIA® is an antibody fragment that blocks Tumor Necrosis Factor (TNF) alpha.
Crohn’s disease is chronic debilitating autoimmune disease that occurs when the immune system inappropriately attacks the gastrointestinal (GI) tract, causing GI symptoms and complications outside the GI tract. The disease affects approximately 500,000 Americans.
RA is a systemic debilitating autoimmune disease that occurs when the immune system inappropriately attacks joint tissue, causing painful chronic inflammation and irreversible destruction of cartilage, tendons and bones, that often results in chronic pain, loss of function and disability, and can also lead to cardiovascular and pulmonary complications. The disease affects more than two million Americans.
CIMZIA® has been available to doctors and patients in the U.S. since April 24, 2008.
XOMA earns royalties on U.S. sales of bacterial cell expression-enabled products, including LUCENTIS® and CIMZIA®, of 0.5 percent to 3.0 percent of sales.
- - -
The above information should not be used as a source for prescribing information.
